Related Experiment Videos
A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis
M I Kaiser-Kupfer1, M A Gazzo, M B Datiles
1Ophthalmic Genetics and Clinical Services Branch, National Eye Institute, National Institutes of Health, Bethesda, Md 20892.
Insights
Topical cysteamine eye drops effectively cleared corneal crystals in nephropathic cystinosis patients. This treatment shows potential for preventing and reversing eye complications in both young and older individuals.
Area of Science:
- Ophthalmology
- Genetics
- Pharmacology
Background:
- Nephropathic cystinosis causes progressive corneal crystal deposition, leading to visual impairment.
- Current treatments focus on systemic management, with limited options for ocular complications.
Purpose of the Study:
- To evaluate the efficacy of topical cysteamine eye drops in treating corneal crystal deposits in nephropathic cystinosis patients.
- To assess the potential for both primary prevention and reversal of ocular complications.
Main Methods:
- A double-masked, randomized, placebo-controlled trial involving 29 patients with nephropathic cystinosis (18 younger than 42 months, 11 aged 4-31 years).
- Patients received either topical cysteamine eye drops or a placebo in a masked fashion.
- Corneal crystal deposition was assessed to compare the effects between treated and fellow eyes.
Main Results:
- Ten patients (8 younger, 2 older) showed marked clearing of corneal crystals in the eye treated with cysteamine.
- No significant difference was observed in 15 patients, potentially due to short treatment duration or poor compliance.
- The study demonstrated cysteamine's efficacy in reducing corneal crystal burden.
Conclusions:
- Topical cysteamine eye drops are effective in clearing corneal crystals in nephropathic cystinosis.
- This therapy offers a promising approach for the primary prevention and reversal of ocular complications associated with cystinosis, even in older patients.
Abstract:
Eighteen patients with nephropathic cystinosis who were younger than 42 months and 11 patients 4 to 31 years of age were entered into a double-masked, randomized, placebo-controlled trial of topical cysteamine eye drops between November 1985 and September 1989. Eight of the younger patients and 2 of the older patients showed marked clearing of corneal crystals in one eye compared with the fellow eye. When the code was broken, all 10 patients were found to have received cysteamine eye drops in the improved eye. Of the remaining 19 patients 4 were unavailable for follow-up. In 15 patients no marked difference was noted between the two eyes. Eight have presumably been in the protocol for too short a time and several have been poor compliers with the therapy. These results not only demonstrate the potential for primary prevention of corneal crystal deposition but also, for the first time, offer the possibility of reversing the corneal complications of cystinosis in older patients.